Clinical Trial Update: Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating DVS-233 SR in combination with venlafaxine ER in adults with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• DVS-233 SR
• Venlafaxine ER (venlafaxine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED